Table 10.
Outcomes predicted by models for one birth cohort in Eur-region
| POLYMODa | Roxanne | CoRoVa | |
|---|---|---|---|
| Undiscounted cases | |||
| Mild | 22,708 | 32,186 | 28,680 |
| Moderate | 10,360 | 14,580 | 10,430 |
| Severe | 1,658 | 2,324 | 1,806 |
| Nosocomial | 415 | 528 | 452 |
| Deaths | 1 | 1 | 1 |
| GP-visits | 12,019 | 14,580 | 10,430 |
| Inpatient (comm. acq.) | 1,658 | 2,324 | 1,860 |
| Discounted savings | |||
| Outpatient | €480,745 | €556,984 | €829,111 |
| Inpatient | €4,643,286 | €5,949,119 | €4,714,920 |
| Indirect | € 1,322,021 | € 2,111,857 | € 2,088,993 |
| Discounted net costs b | € 9,032,932 | € 9,842,807 | € 9,518,208 |
| Discounted QALYs | |||
| Mortality | 25 | 27 | 26 |
| Morbidity | 131 | 166 | 142 |
a. Approximations for one cohort from the multi-cohort results; b. Health-care perspective.